Completed Antibiotic Course
Patient finishes the recommended antibiotic regimen for Lyme disease.
- 14–21 d: Typical course (Doxycycline standard)
- Oral: Route (IV for late disease)
- High: Adherence (Placeholder metric)
- Scheduled: Follow-up (Post-tx check)
Placeholder section heading
Short placeholder text about completing treatment.
Spirochete Clearance Confirmed
Serologic and clinical markers indicate the infection is resolved.
- Clinical: Clearance marker (No direct test of cure)
- Persists: Serology (Antibodies remain positive)
- Low: Reinfection risk (Placeholder value)
- ~1 mo: Timeframe (Post-treatment)
Placeholder section heading
Short placeholder text about clearance confirmation.
Persistent Fatigue and Arthralgia
Some patients report ongoing fatigue and joint pain despite cure.
- ~10-20%: PTLDS fatigue (Placeholder estimate)
- Common: Arthralgia (Placeholder descriptor)
- >6 mo: Duration (Defines PTLDS)
- Variable: Severity (Placeholder value)
Placeholder section heading
Short placeholder text about fatigue and arthralgia.
Cognitive Impairment Symptoms
Brain fog, memory, and concentration complaints may persist.
- Reported: Brain fog (Placeholder descriptor)
- Mild deficit: Memory (Placeholder estimate)
- Reduced: Concentration (Placeholder value)
- Functional: Impact (Placeholder descriptor)
Placeholder section heading
Short placeholder text about cognitive symptoms.
PTLDS Risk Factor Assessment
Delayed diagnosis and disseminated stage raise PTLDS likelihood.
- Key factor: Delayed dx (Placeholder descriptor)
- Key factor: Disseminated stage (Placeholder descriptor)
- Protective: Early treatment (Placeholder descriptor)
- Computed: Risk gauge (From sliders)
Placeholder section heading
Short placeholder text about risk factors.
Placeholder highlight: earlier treatment lowers PTLDS risk.